164 related articles for article (PubMed ID: 17671332)
41. Comparative evaluation of novel biodegradable nanoparticles for the drug targeting to breast cancer cells.
Mattu C; Pabari RM; Boffito M; Sartori S; Ciardelli G; Ramtoola Z
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):463-72. PubMed ID: 23916461
[TBL] [Abstract][Full Text] [Related]
42. Effects of PEG tethering chain length of vitamin E TPGS with a Herceptin-functionalized nanoparticle formulation for targeted delivery of anticancer drugs.
Zhao J; Feng SS
Biomaterials; 2014 Mar; 35(10):3340-7. PubMed ID: 24461325
[TBL] [Abstract][Full Text] [Related]
43. HER2/neu antibody conjugated poly(amino acid)-coated iron oxide nanoparticles for breast cancer MR imaging.
Yang HM; Park CW; Woo MA; Kim MI; Jo YM; Park HG; Kim JD
Biomacromolecules; 2010 Nov; 11(11):2866-72. PubMed ID: 20932000
[TBL] [Abstract][Full Text] [Related]
44. [Herceptin-based therapy for breast cancer].
Tokuda Y; Saito Y; Suzuki Y
Nihon Rinsho; 2006 Mar; 64(3):540-5. PubMed ID: 16529047
[TBL] [Abstract][Full Text] [Related]
45. Biodegradable nanoparticles for direct or two-step tumor immunotargeting.
Nobs L; Buchegger F; Gurny R; Allémann E
Bioconjug Chem; 2006; 17(1):139-45. PubMed ID: 16417262
[TBL] [Abstract][Full Text] [Related]
46. Targeted Ultrasound-Triggered Phase Transition Nanodroplets for Her2-Overexpressing Breast Cancer Diagnosis and Gene Transfection.
Gao D; Gao J; Xu M; Cao Z; Zhou L; Li Y; Xie X; Jiang Q; Wang W; Liu J
Mol Pharm; 2017 Apr; 14(4):984-998. PubMed ID: 28282145
[TBL] [Abstract][Full Text] [Related]
47. Cell studies of a three-component antisense MORF/tat/Herceptin nanoparticle designed for improved tumor delivery.
Liu X; Wang Y; Nakamura K; Kubo A; Hnatowich DJ
Cancer Gene Ther; 2008 Feb; 15(2):126-32. PubMed ID: 18084241
[TBL] [Abstract][Full Text] [Related]
48. A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity.
Yao X; Jiang J; Wang X; Huang C; Li D; Xie K; Xu Q; Li H; Li Z; Lou L; Fang J
Breast Cancer Res Treat; 2015 Aug; 153(1):123-33. PubMed ID: 26253944
[TBL] [Abstract][Full Text] [Related]
49. Multifunctional poly(D,L-lactide-co-glycolide)/montmorillonite (PLGA/MMT) nanoparticles decorated by Trastuzumab for targeted chemotherapy of breast cancer.
Sun B; Ranganathan B; Feng SS
Biomaterials; 2008 Feb; 29(4):475-86. PubMed ID: 17953985
[TBL] [Abstract][Full Text] [Related]
50. The molecular analysis of breast cancer utilizing targeted nanoparticle based ultrasound contrast agents.
Sakamoto JH; Smith BR; Xie B; Rokhlin SI; Lee SC; Ferrari M
Technol Cancer Res Treat; 2005 Dec; 4(6):627-36. PubMed ID: 16292882
[TBL] [Abstract][Full Text] [Related]
51. A kit to prepare (111)In-DTPA-trastuzumab (Herceptin) Fab fragments injection under GMP conditions for imaging or radioimmunoguided surgery of HER2-positive breast cancer.
Scollard DA; Chan C; Holloway CM; Reilly RM
Nucl Med Biol; 2011 Jan; 38(1):129-36. PubMed ID: 21220136
[TBL] [Abstract][Full Text] [Related]
52. Ultrasonic-responsive piezoelectric stimulation enhances sonodynamic therapy for HER2-positive breast cancer.
Chen Z; Yang L; Yang Z; Wang Z; He W; Zhang W
J Nanobiotechnology; 2024 Jun; 22(1):369. PubMed ID: 38918812
[TBL] [Abstract][Full Text] [Related]
53. Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patients.
Sperinde J; Jin X; Banerjee J; Penuel E; Saha A; Diedrich G; Huang W; Leitzel K; Weidler J; Ali SM; Fuchs EM; Singer CF; Köstler WJ; Bates M; Parry G; Winslow J; Lipton A
Clin Cancer Res; 2010 Aug; 16(16):4226-35. PubMed ID: 20664024
[TBL] [Abstract][Full Text] [Related]
54. Uptake of plasmid-loaded nanoparticles in breast cancer cells and effect on Plk1 expression.
Steinhauser I; Langer K; Strebhardt K; Spänkuch B
J Drug Target; 2009 Sep; 17(8):627-37. PubMed ID: 19591537
[TBL] [Abstract][Full Text] [Related]
55. Targeting endothelin A receptor enhances anti-proliferative and anti-invasive effects of the HER2 antibody trastuzumab in HER2-overexpressing breast cancer cells.
Fischgräbe J; Götte M; Michels K; Kiesel L; Wülfing P
Int J Cancer; 2010 Aug; 127(3):696-706. PubMed ID: 19960438
[TBL] [Abstract][Full Text] [Related]
56. Trastuzumab-polyethylenimine-polyethylene glycol conjugates for targeting Her2-expressing tumors.
Germershaus O; Merdan T; Bakowsky U; Behe M; Kissel T
Bioconjug Chem; 2006; 17(5):1190-9. PubMed ID: 16984128
[TBL] [Abstract][Full Text] [Related]
57. Anionic amino acid dendrimer-trastuzumab conjugates for specific internalization in HER2-positive cancer cells.
Miyano T; Wijagkanalan W; Kawakami S; Yamashita F; Hashida M
Mol Pharm; 2010 Aug; 7(4):1318-27. PubMed ID: 20527783
[TBL] [Abstract][Full Text] [Related]
58. Targeting HER2-positive cancer with dolastatin 15 derivatives conjugated to trastuzumab, novel antibody-drug conjugates.
Gianolio DA; Rouleau C; Bauta WE; Lovett D; Cantrell WR; Recio A; Wolstenholme-Hogg P; Busch M; Pan P; Stefano JE; Kramer HM; Goebel J; Krumbholz RD; Roth S; Schmid SM; Teicher BA
Cancer Chemother Pharmacol; 2012 Sep; 70(3):439-49. PubMed ID: 22821053
[TBL] [Abstract][Full Text] [Related]
59. Bioconjugated gold nanoparticles as a molecular based contrast agent: implications for imaging of deep tumors using optoacoustic tomography.
Copland JA; Eghtedari M; Popov VL; Kotov N; Mamedova N; Motamedi M; Oraevsky AA
Mol Imaging Biol; 2004; 6(5):341-9. PubMed ID: 15380744
[TBL] [Abstract][Full Text] [Related]
60. Targeted delivery of multifunctional magnetic nanoparticles.
McCarthy JR; Kelly KA; Sun EY; Weissleder R
Nanomedicine (Lond); 2007 Apr; 2(2):153-67. PubMed ID: 17716118
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
